Skip to Main Content
Donald Trump
chronic disease
FDA
Reporting from the frontiers of health and medicine
STAT Events Treatment Evolutions in Advanced Breast Cancer
  • Virtual

Treatment Evolutions in Advanced Breast Cancer

Where

Virtual

When

{{getUserDateTimezone("1738260000").singleDate}}
{{getUserDateTimezone("1738260000").time}} - {{getUserDateTimezone("1738261800").time}} {{getClientTimezoneName()}}

About

Precision medicine, targeted treatments, and actionable biomarker testing are transforming the treatment landscape for breast cancer. In this STAT Brand Studio virtual event, one clinical expert addresses existing challenges in the second-line treatment setting for patients with HR+/HER2- locally advanced or metastatic breast cancer. She also shares how the latest advances have the potential to help redefine the treatment paradigm for patients with qualifying alterations who experience tumor progression on, or resistance to widely used first-line therapies.

Moderator

Britt Whitmore, Executive Producer of STAT Brand Studio

Speakers

Dr. Maria Theodoulou, MD, Program Director, Breast Cancer Medicine at New York Oncology Hematology (NYOH) in Albany, NY

Dr. Maria Theodoulou, MD is a Medical Oncologist, currently practicing at New York Oncology Hematology (NYOH) in Albany, NY. With over 36 years’ experience, she is recognized internationally for her breast cancer research and for treating both early and advanced stage breast cancer patients, male and female, of all ages. The focus of her research has included novel chemotherapy, biologic and immunotherapy in the treatment of breast cancer. She has also worked extensively in expanding understanding of hormonal agents in both early and advanced stage breast cancer. Prior to joining NYOH, she was an attending physician at Memorial Sloan Kettering Cancer Center, and a Professor of Medicine at the Joan and Sanford Weill Medical College of Cornell University, both in New York City.

 

©2024 AstraZeneca. All rights reserved. US-96373 Last Updated 12/24

  • AstraZeneca